BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 28464343)

  • 1. Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms.
    Coyle C; Crawford G; Wilkinson J; Thomas SJ; Bytzer P
    Aliment Pharmacol Ther; 2017 Jun; 45(12):1524-1533. PubMed ID: 28464343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease.
    Wilkinson J; Wade A; Thomas SJ; Jenner B; Hodgkinson V; Coyle C
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):86-93. PubMed ID: 30272584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
    Sun J; Yang C; Zhao H; Zheng P; Wilkinson J; Ng B; Yuan Y
    Aliment Pharmacol Ther; 2015 Oct; 42(7):845-54. PubMed ID: 26228097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor.
    Reimer C; Lødrup AB; Smith G; Wilkinson J; Bytzer P
    Aliment Pharmacol Ther; 2016 Apr; 43(8):899-909. PubMed ID: 26909885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease.
    Thomas E; Wade A; Crawford G; Jenner B; Levinson N; Wilkinson J
    Aliment Pharmacol Ther; 2014 Mar; 39(6):595-602. PubMed ID: 24471505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alginate antacid (Gaviscon DA) chewable tablets reduce esophageal acid exposure in Chinese patients with gastroesophageal reflux disease and heartburn symptoms.
    Yuan YZ; Fang JY; Zou DW; Levinson N; Jenner B; Wilkinson J
    J Dig Dis; 2016 Nov; 17(11):725-734. PubMed ID: 27622897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial.
    Pouchain D; Bigard MA; Liard F; Childs M; Decaudin A; McVey D
    BMC Gastroenterol; 2012 Feb; 12():18. PubMed ID: 22361121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gaviscon® Advance alone versus co-prescription of Gaviscon® Advance and proton pump inhibitors in the treatment of laryngopharyngeal reflux.
    Wilkie MD; Fraser HM; Raja H
    Eur Arch Otorhinolaryngol; 2018 Oct; 275(10):2515-2521. PubMed ID: 30062580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of action, efficacy, and onset dynamics of a single dose of alginates in patients with heartburn and GERD].
    Bordin DS; Masharova AA; Firsova LD; Kozhurina TS; Safonova OV
    Eksp Klin Gastroenterol; 2009; (4):77-85. PubMed ID: 19960998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Failure of amiodarone in supraventricular tachycardia in an infant: drug interaction with Gaviscon(®)?].
    Chantepie A; Lefort B; Méot M; Jandali JC; Soulé N; Chantreuil J; Vaillant MC; Tisseron B
    Arch Pediatr; 2014 Jun; 21(6):663-4. PubMed ID: 24768351
    [No Abstract]   [Full Text] [Related]  

  • 11. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux.
    Mandel KG; Daggy BP; Brodie DA; Jacoby HI
    Aliment Pharmacol Ther; 2000 Jun; 14(6):669-90. PubMed ID: 10848650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised clinical trial: the effectiveness of Gaviscon Advance vs non-alginate antacid in suppression of acid pocket and post-prandial reflux in obese individuals after late-night supper.
    Deraman MA; Abdul Hafidz MI; Lawenko RM; Ma ZF; Wong MS; Coyle C; Lee YY
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1014-1021. PubMed ID: 32343001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients.
    Sweis R; Kaufman E; Anggiansah A; Wong T; Dettmar P; Fried M; Schwizer W; Avvari RK; Pal A; Fox M
    Aliment Pharmacol Ther; 2013 Jun; 37(11):1093-102. PubMed ID: 23600790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study.
    De Ruigh A; Roman S; Chen J; Pandolfino JE; Kahrilas PJ
    Aliment Pharmacol Ther; 2014 Sep; 40(5):531-7. PubMed ID: 25041141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two placebo-controlled crossover studies in healthy subjects to evaluate gastric acid neutralization by an alginate-antacid formulation (Gaviscon Double Action).
    Wilkinson J; Abd-Elaziz K; den Daas I; Wemer J; van Haastert M; Hodgkinson V; Foster M; Coyle C
    Drug Dev Ind Pharm; 2019 Mar; 45(3):430-438. PubMed ID: 30470147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of a liquid alginate suspension (Gaviscon Advance) in the management of laryngopharyngeal reflux.
    McGlashan JA; Johnstone LM; Sykes J; Strugala V; Dettmar PW
    Eur Arch Otorhinolaryngol; 2009 Feb; 266(2):243-51. PubMed ID: 18506466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Estimation of efficiency of alginate-raft barrier in treatment of gastroesophageal reflux disease].
    Bordin DS; Masharova AA; Firsova LD; Kozhurina TS; Safonova OV
    Eksp Klin Gastroenterol; 2008; (6):77-81. PubMed ID: 19334430
    [No Abstract]   [Full Text] [Related]  

  • 18. [Alginate-raft preparations in the treatment of acid reflux and heartburn (literature review)].
    Mandel KG; Deggi BP; Brodi DA; Jeykobi GI
    Eksp Klin Gastroenterol; 2008; (4):64-77. PubMed ID: 19145905
    [No Abstract]   [Full Text] [Related]  

  • 19. [Restoration of the quality of life by eliminating and prevention of heartburn by alginate: results of multicenter study "VIA APIA"].
    Lazebnik LB; Bordin DS; Masharova AA; Dzhulaĭ GS; Butov MA; Abdulkhakov RA; Eremina EIu; Tarasova LV; Safonova OV; Firsova LD; Kozhurina TS
    Eksp Klin Gastroenterol; 2010; (6):70-6. PubMed ID: 20731169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Using gaviscon preparation for relief of esophageal, extraesophageal syndromes and functional dyspepsia in elderly patients with GERD].
    Onuchina EV; Brikova SI; Tsukanov VV
    Eksp Klin Gastroenterol; 2010; (10):80-6. PubMed ID: 21434379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.